These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12586628)

  • 1. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
    Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
    Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
    Ibom VK; Prosnitz RG; Gong JZ; Moore JO; DeCastro CM; Prosnitz LR; Rizzieri DA; Gockerman JP
    Clin Lymphoma; 2003 Sep; 4(2):115-8. PubMed ID: 14556684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
    Rehwald U; Schulz H; Reiser M; Sieber M; Staak JO; Morschhauser F; Driessen C; Rudiger T; Muller-Hermelink K; Diehl V; Engert A;
    Blood; 2003 Jan; 101(2):420-4. PubMed ID: 12509381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in lymphocyte-predominant Hodgkin disease.
    Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
    Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
    Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
    Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
    Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
    Anagnostopoulos I; Hansmann ML; Franssila K; Harris M; Harris NL; Jaffe ES; Han J; van Krieken JM; Poppema S; Marafioti T; Franklin J; Sextro M; Diehl V; Stein H
    Blood; 2000 Sep; 96(5):1889-99. PubMed ID: 10961891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
    Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
    Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
    J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Kaya H; Keung YK; Case D; Cruz JM; Perry JJ; Radford JE; Hurd DD
    Biol Blood Marrow Transplant; 2002; 8(10):544-9. PubMed ID: 12434949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
    Colombat P; Salles G; Brousse N; Eftekhari P; Soubeyran P; Delwail V; Deconinck E; Haïoun C; Foussard C; Sebban C; Stamatoullas A; Milpied N; Boué F; Taillan B; Lederlin P; Najman A; Thièblemont C; Montestruc F; Mathieu-Boué A; Benzohra A; Solal-Céligny P
    Blood; 2001 Jan; 97(1):101-6. PubMed ID: 11133748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
    Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
    Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.